New Helicobacter pylori Eradication Therapies.
10.4166/kjg.2018.72.5.237
- Author:
Jae Yong PARK
1
;
Jae Gyu KIM
Author Information
1. Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. jgkimd@cau.ac.kr
- Publication Type:Review
- Keywords:
Helicobacter pylori;
Therapeutics;
Guideline;
Korea
- MeSH:
Anti-Bacterial Agents;
Bismuth;
Clarithromycin;
Consensus;
Drug Resistance, Microbial;
Helicobacter pylori*;
Helicobacter*;
Incidence;
Korea;
Prevalence;
Stomach Neoplasms
- From:The Korean Journal of Gastroenterology
2018;72(5):237-244
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
While the prevalence of Helicobacter pylori (H. pylori) infection is decreasing in Korea, the incidence of gastric cancer remains high, emphasizing the importance of H. pylori eradication. A new treatment strategy is needed as the eradication rate with standard triple therapy, which is currently the standard first-line regimen for H. pylori infection, has decreased below the optimum level. The major cause of eradication failure is increased antibiotic resistance. Sequential, concurrent, and hybrid therapies that include clarithromycin produce higher eradication rates than conventional standard triple therapy. However, the effectiveness of these treatments is limited in regions where the resistance rate to various antibiotics is high. Bismuth quadruple therapy is another alternative therapy, but again the eradication rate is not sufficiently high. Tailored therapy based on individual characteristics, including antibiotic susceptibility, may be ideal, but there are several limitations for clinical application and further research is needed. New potassium-competitive acid blocker-based therapies could emerge as effective alternatives in the near future. A consensus is needed to establish a strategy for applying new eradication therapies in Korea.
